Research in the Calfee Lab has three parallel and complimentary areas of focus, all of which share the ultimate goal of deepening our understanding of the pathogenesis of the acute respiratory distress syndrome (ARDS) so as to improve prevention and treatment strategies.  First, we are interested in novel approaches to molecular phenotyping of ARDS and advancing precision medicine for ARDS, including the identification of ARDS subphenotypes.  Second, we are investigating the epidemiologic and mechanistic relationship between tobacco products and acute lung injury/ARDS, with recent extensions to air pollution and the acute pulmonary impact of e-cigarette use.  Third, we are interested in novel treatment strategies for ARDS, sepsis, and related conditions and participate in multiple clinical trials of novel therapies. In 2020, we expanded our focus to include COVID-19, given its frequent progression to ARDS, and are helping to lead an observational cohort study (COMET; link here) and a Phase 2 platform clinical trial (ISPY COVID; link here).